AB604 creates a new statutory subsection (49.45(62)) that directs the Wisconsin Department of Health Services (DHS) to seek a federal Medicaid waiver to run a demonstration project providing prerelease Medical Assistance coverage for certain incarcerated individuals. The coverage would extend for up to 90 days before release and include case management, medication‑assisted treatment (MAT) for substance use disorders, and a 30‑day supply of prescription medications for people who would otherwise be eligible for Medical Assistance.
The bill matters because federal Medicaid rules generally bar payment for inmate care in correctional facilities; a Section 1115‑style waiver would be required to fund prerelease services. If HHS approves the waiver, DHS must provide reimbursement—federal and state shares—to the extent authorized, which creates operational, regulatory, and budgetary questions for DHS, correctional agencies, community treatment providers, and pharmacies ahead of the submission deadline of January 1, 2027.
At a Glance
What It Does
The bill requires DHS to request a federal waiver to permit Medicaid reimbursement for three prerelease services—case management, MAT for all substance use disorders, and a 30‑day medication supply—delivered up to 90 days before a person’s release from incarceration. If the waiver is granted, DHS must reimburse those services to the extent HHS approves.
Who It Affects
The rule targets incarcerated people who would otherwise qualify for Wisconsin Medical Assistance, correctional health units that must coordinate prerelease care, community behavioral health providers and pharmacies that will receive Medicaid payments, and DHS as the implementing agency responsible for the waiver and claims processing.
Why It Matters
This creates a path for Medicaid to fund prerelease continuity of care in Wisconsin—an intervention tied to lowering postrelease overdoses and treatment gaps—but it also shifts implementation and funding details into the waiver negotiation and state administrative systems.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB604 does not itself change Medicaid eligibility; instead it directs DHS to ask the federal government for permission to use Medicaid dollars before release. Under current federal law, Medicaid generally cannot be used to pay for services provided to people while they are incarcerated.
The bill instructs DHS to pursue a waiver so Wisconsin can run a demonstration project that funds case management, medication‑assisted treatment, and a 30‑day supply of prescribed drugs during the up-to‑90‑day prerelease window for people who remain otherwise eligible for Medical Assistance.
Practically, approval will require DHS to define who qualifies, how services are documented and billed, and how care transitions to community providers after release. Medication‑assisted treatment raises specialized requirements: some MAT (for example methadone) is delivered through certified opioid treatment programs (OTPs) and federal and DEA rules govern dispensing and take‑home supplies.
The bill’s instruction to cover “all types” of substance use disorders broadens the policy intent, but actual service availability will depend on medically appropriate options and provider capacity in the community.If HHS approves the waiver, the state will implement billing and reimbursement for both federal and state shares “to the extent approved,” which means the waiver’s terms will determine what services and timeframes are covered and how costs are split. The statute also sets a hard deadline for DHS to submit the waiver request by January 1, 2027, so DHS must resolve operational, legal, and data‑sharing questions with corrections agencies and providers before that date.
The Five Things You Need to Know
The bill creates a new statutory subsection, 49.45(62), authorizing DHS to pursue a waiver to provide prerelease Medical Assistance coverage.
It limits prerelease coverage to three service categories: case management, medication‑assisted treatment for substance use disorders, and a 30‑day supply of prescription medications.
Coverage under the demonstration may begin up to 90 days before an individual’s release, but only for people otherwise eligible for Medical Assistance.
If HHS approves the waiver, DHS must provide reimbursement for both the federal and nonfederal share of approved services to the extent the waiver authorizes them.
DHS must submit the waiver request no later than January 1, 2027.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
What prerelease services the demonstration may cover
This subsection lists the three service categories the waiver request must target: (1) case management, (2) medication‑assisted treatment for all types of substance use disorders, and (3) a 30‑day supply of prescription medications. The provision caps the prerelease window at 90 days prior to release and conditions coverage on the person being otherwise eligible for Medical Assistance. For implementers, this means the waiver application must specify clinical definitions, provider types, and the enrollment and documentation rules that will make these services billable under Medicaid during incarceration.
Reimbursement if waiver is approved
This subsection requires DHS to provide reimbursement under Medical Assistance for both the federal and nonfederal shares of any services the federal government authorizes in the waiver. The phrasing—'to the extent approved under the waiver'—makes state payment obligations contingent on the waiver’s scope, and it places the fiscal and claims‑processing burden on DHS to align state systems with whatever HHS approves.
Deadline to submit the waiver request
A separate nonstatutory provision directs DHS to submit the waiver request no later than January 1, 2027. That timeline forces DHS to resolve major operational issues—eligibility verification, corrections coordination, provider networks, controlled‑substance dispensing rules, IT and claims flows—before the deadline, or to present a waiver that phases in services as those obstacles are addressed.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Incarcerated people with substance use disorders: They gain access to evidence‑based treatments and uninterrupted medications in the weeks before release, which reduces the high risk of overdose and treatment dropout after reentry.
- Community behavioral health and primary care providers: Successful prerelease enrollment creates clearer pathways for follow‑up appointments and reimbursed services, increasing revenue predictability for clinics that accept Medicaid.
- Families and communities: Better prerelease stabilization and medication continuity can lower emergency health crises and short‑term public safety incidents after release, improving outcomes for families and local systems.
- State public health agencies: The project gives DHS a lever to reduce population‑level harms (like postrelease overdose deaths) and to collect data on the impact of prerelease Medicaid coverage.
Who Bears the Cost
- Wisconsin DHS and the state Medicaid budget: DHS must design and administer the waiver application, coordinate implementation, and cover state share obligations to the extent the waiver requires nonfederal spending.
- County and municipal corrections authorities: Facilities must build operational agreements with DHS and providers, adjust release planning workflows, and support eligibility verification and medication logistics.
- Community treatment providers and pharmacies: Providers will need to expand intake capacity, meet Medicaid billing requirements, and comply with controlled‑substance regulations for prerelease dispensing, which may require new staffing and systems.
- Local taxpayers (indirectly): If the waiver requires a state match for the nonfederal share or mandates additional state administrative spending, those costs flow to state budgets funded by taxpayers.
Key Issues
The Core Tension
The central dilemma is balancing public‑health gains from continuous prerelease care—lower overdoses, fewer emergency interventions, better long‑term outcomes—against fiscal, regulatory, and operational burdens on state Medicaid, corrections systems, and community providers; the bill pushes the problem into a federal waiver process where solving one side of the equation (funding services) may create hard demands on the other (controlled‑substance rules, staffing, and state matching dollars).
AB604's policy goal—using Medicaid to smooth the transition from incarceration to community care—runs into several unresolved implementation and legal issues. First, federal approval is not automatic: HHS will evaluate whether the proposed demonstration fits within permissible waiver authority and whether it safeguards program integrity.
The statute leaves precise program design to the waiver, so critical details (eligibility verification while incarcerated, billing mechanisms, service limits, and performance measures) are undecided until HHS weighs in. Second, the MAT and 30‑day medication provisions collide with federal and DEA rules governing controlled substances.
Some medications (notably methadone) require delivery through certified opioid treatment programs and have strict take‑home limits, so operationalizing a 30‑day prerelease supply may require creative solutions like bridging prescriptions, coordination with OTPs, or state regulatory changes.
Third, administrative capacity is a material constraint: corrections facilities, DHS, community providers, and pharmacies must exchange protected health information, enroll people in Medicaid where coverage lapsed, and handle claims and prior authorizations on a compressed timeline. Provider capacity in many regions is already limited, so the demonstration could increase demand beyond supply and produce uneven geographic access.
Finally, the statute conditions state payment on what HHS approves, but it does not specify whether DHS must implement services if HHS authorizes only a subset; that leaves open questions about phased rollouts and equitable coverage across counties.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.